Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results

Rhea-AI Summary

Clearside Biomedical (NASDAQ:CLSD) will host a conference call on November 9, 2022, at 8:30 a.m. ET to discuss results from its OASIS Phase 1/2a clinical trial of CLS-AX for treating wet AMD patients. The company will also release its financial results for Q3 2022 on the same day. The conference will include key opinion leader Arshad Khanani, M.D., and both live and archived webcasts will be available for investors. Clearside specializes in innovative therapy delivery to the eye through its proprietary SCS Microinjector.

Positive

• Hosting a conference call to discuss promising trial results, indicating transparency and investor engagement.

Negative

• None.

Webcast and Conference Call on Wednesday, November 9, 2022 at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Arshad Khanani, M.D.

ALPHARETTA, Ga., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®), announced today that the Company will host a conference call on Wednesday, November 9, 2022 at 8:30 a.m. Eastern Time to report results from its OASIS Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in neovascular age-related macular degeneration (wet AMD) patients. As previously announced, on November 9, 2022, Clearside will also report its financial results for the quarter ended September 30, 2022.

The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (888) 506-0062 (domestic) or (973) 528-0011 (international) and entering conference code: 111701. An archive of the webcast will be available for three months.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector^®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE^® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. For more information, please visit www.clearsidebio.com.

Investor and Media Contact:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.

FAQ

What are the main updates from Clearside Biomedical's conference call on November 9, 2022?

Clearside Biomedical will report results from its OASIS Phase 1/2a clinical trial of CLS-AX for wet AMD and Q3 2022 financial results.

How can I access the webcast for Clearside Biomedical's November 9 conference call?

The live and archived webcast can be accessed on Clearside's website in the Investors section.

What is the focus of Clearside Biomedical's clinical trial being discussed on November 9, 2022?

The focus is on the OASIS Phase 1/2a clinical trial of CLS-AX in patients with neovascular age-related macular degeneration.

Who will be participating in the conference call on November 9, 2022?

Key opinion leader Arshad Khanani, M.D., will participate alongside Clearside's management.